Investment Rating - The report does not provide a specific investment rating for the industry Core Insights - The Namibia Essential Medicines List (NEMList) is a critical document for ensuring the availability and accessibility of essential medicines in Namibia, aimed at improving public health outcomes [10][12][19] - The seventh edition of the NEMList reflects updates based on current clinical evidence, morbidity patterns, and treatment standards, ensuring that it remains relevant to the healthcare needs of the population [13][30] - A total of 298 items were deleted from the NEMList, including 41 antineoplastics, to align with the Standard Treatment Guidelines (STGs) focused on primary healthcare [31][32] - The introduction of the NiMART category replaces the previous IMAI-R category, allowing for better management of antiretroviral therapy at designated health facilities [32][56] Summary by Sections How to Use the Seventh Edition of the NEMList - The NEMList contains essential pharmaceutical items selected to meet the healthcare needs of the Namibian population at an affordable cost [29] - The document is structured to facilitate easy navigation and understanding of the essential medicines available [34][35] Restricted Use Classification - The NEMList includes categories for Restricted Use (R) and NiMART items, which require specific control measures and monitoring to prevent misuse [56][60] - NiMART items are available at designated health centers and require trained staff for their administration [56][58] The Namibian Essential Medicines List - The NEMList is organized according to therapeutic groups, allowing healthcare providers to easily identify necessary medications [67] - Each medicine is classified based on its availability and importance, guiding procurement and prescribing practices [21][24] Annexes - The annexes provide forms and guidelines for requesting changes to the NEMList and STGs, streamlining the process for healthcare professionals [25][54]

Investment Rating - The report does not explicitly provide an investment rating for the healthcare industry or specific companies within it. Core Insights - The Universal Health Coverage (UHC) aims to provide equitable and sustainable access to essential health products at affordable prices across all levels of the healthcare system [4]. - The World Health Organization (WHO) has established a Model List of Essential Medicines, which serves as a guideline for countries to adopt or adapt according to local priorities [4]. - Mauritania has revised its National List of Essential Medicines (LNME) multiple times, with the latest revision in March 2021, which will be effective from 2024 to 2026 [5][6]. - The new LNME includes essential medicines for both adults and children, introduces a list of essential medical consumables, identifies 40 tracer products, and incorporates the WHO's AWaRe classification of antibiotics to combat antimicrobial resistance [7]. Summary by Sections Section I: Overview of Essential Medicines - Essential medicines must meet the majority of the population's health needs, be effective, of proven quality, easy to use, available at all times, have minimal side effects, and be financially accessible [12]. Section II: National List of Essential Medicines - The LNME is organized into 31 therapeutic classes, with medicines listed alphabetically by their International Nonproprietary Name (INN) [13]. - The list includes various columns detailing therapeutic class, INN, pharmaceutical form, dosage, and the AWaRe classification for antibiotics [13][16]. Section III: Implementation and Monitoring - A roadmap has been developed outlining key guidelines, activities, and performance indicators for the implementation of the LNME [8]. - The adoption of the LNME involved participation from prescribers, dispensers, managers, and civil society, ensuring a comprehensive approach to healthcare delivery [7]. Section IV: Regulatory Framework - The application of the LNME is mandatory for certain healthcare levels and serves as a guideline for others, with revisions occurring every two years [22][23].

Investment Rating - The report does not provide a specific investment rating for the industry. Core Insights - The report outlines the establishment of the National List of Essential Medicines and Biomedical Materials (LNME) in Côte d'Ivoire, aimed at ensuring the availability of essential pharmaceuticals and medical devices to meet public health needs [7][8]. - The LNME is designed for public health facilities, associated health establishments, and other stakeholders involved in the supply chain of essential medicines [8][9]. - The report emphasizes the importance of having a comprehensive list of essential medicines categorized into primary and complementary lists, which are to be made available at all times by purchasing centers for public health facilities [9][10]. Summary by Sections General Provisions - The report defines essential medicines and biomedical materials as products that meet the health needs of the majority of the population and align with national health priorities [6][7]. - It establishes the LNME's purpose, which is to define and regulate the essential medicines and biomedical materials available in the country [7][8]. Specific Articles - Article 1 outlines the definitions related to essential medicines and biomedical materials, including the authorization levels for health establishments to prescribe and dispense these products [5][6]. - Article 2 states that the LNME is intended for various health establishments, including public hospitals and private health facilities [8]. - Article 3 specifies that the use of products from the LNME is dependent on the authorization level of the health establishments [9]. - Article 4 discusses the availability of essential medicines and biomedical materials, ensuring they are accessible at all times [9][10]. Appendices - The report includes detailed lists of essential medicines categorized by therapeutic classes, including analgesics, anesthetics, anti-infectives, and more [19][20]. - The appendices also provide a pediatric list of essential medicines specifically for children aged 0 to 12 years [12][24]. - The biomedical materials section includes essential consumables for various medical procedures and treatments [22][23].

Investment Rating - The report does not provide a specific investment rating for the industry Core Insights - The WHO design principles and tools aim to enhance the usability and impact of WHO guidelines by focusing on the needs of end users and improving implementation at the country level [2][3] - The development of these principles involved extensive co-design workshops with participants from 15 countries, emphasizing a user-centered approach [8][9] - The principles are designed to be complementary to existing WHO documentation and informed by user feedback to ensure relevance and effectiveness [4][5] Summary by Sections Design Principles - The design principles include: 1. Design with empathy by understanding people and their context 2. Design for living guidelines 3. Design for accessibility 4. Design for clarity 5. Design for translation to multiple languages [13][21] Tools for Implementation - Relevant tools developed to support the design principles include: - T1: Stakeholder network map - T2: Enablers and barriers - T3: Empathy map - T4: Guideline journey mapping - T5: Annotated sample guideline chapter - T6: Design guide - T7: Translated sample guideline page [15][40][46] Development Process - The principles were developed over two years through four workshops, focusing on improving accessibility, clarity, and translation [8][11][12] - Insights from over 70 end-users were gathered to identify barriers in guideline use and inform the design process [7][8] Focus Areas - Emphasis on understanding the unique circumstances of guideline users to enhance implementation [22] - Guidelines should be treated as living documents that can be updated easily to reflect new evidence [26] - Accessibility is crucial, ensuring guidelines are usable by individuals with various impairments and available across multiple platforms [30] - Clarity in communication is essential, with guidelines written in plain language and structured for easy navigation [35] - Consideration for translation is necessary to accommodate diverse languages and cultural contexts [38]

空气污染与健康工作者培 训工具包（APHT） 空气污染的健康影响 ：一般概述 注释 • 世界卫生组织（WHO）模块的参考编号 空气污染的健康影响：一般概述 是 WHO/HEP/ECH/AQE/2024.5 © WHO 2024. 保留一些权利。此作品可在以下条件下使用： CC BY-NC- SA 3.0 IGO 许可证 本模块包含大量幻灯片，演讲者应从中选择最相关的内容用于特定演示。这些幻灯片涵盖了问题的多个方面。仅展示与当地 或区域情况最直接相关的幻灯片。如有需要，可以根据本模块演示的特定语境调整每个幻灯片中的信息、统计数据和照片。 本模块属于针对卫生工作者的空气污染与健康培训工具包（APHT）。该工具包是在政府机构、世界卫生组织合作中心、非 国家行为者（包括医学和环境卫生协会）以及学术机构等30多位专家的协作下开发的。其开发方法包括对现有针对卫生工作 者的空气污染和健康培训机会的梳理，以了解全球材料的需求和差距。通过与世界卫生组织的现有合作，专家们对培训模块 的大纲定义和内容填充做出了贡献。由世界卫生组织协调的同行评审和试点测试确保了收集反馈和输入，以最终确定产品。 世界卫生组织在专业知识、经验和整体可行 ...

空气污染与卫生工作者培 训工具包（APHT） 环境空气污染简 介 注释 • 世界卫生组织（WHO）模块的参考编号 环境空气污染简介 是 WHO/HEP/ECH/AQE/2024.3 © WHO 2024. 一些权利保留 。此作品可在以下条件下获取： CC BY-NC-SA 3.0 IGO 许可证。 • 本模块包含大量幻灯片，演讲人应从中选择最有相关性的幻灯片用于特定呈现。这些幻灯片涵盖了问题的多方面。仅播放那 些最直接符合当地或地区情况的幻灯片。在相关的情况下，您可以调整每页幻灯片中的信息、统计数据以及图片，以匹配本 模块呈现的特定情境。 本模块属于针对卫生工作者的空气污染与健康培训工具包（APHT）。该工具包是在与来自政府部门、世界卫生组织合作中 心、非国家行为者（包括医学和环境健康协会）以及学术机构等30多位专家的协作下开发的。开发过程中采用的方法包括对 现有针对卫生工作者的空气污染与健康培训机会进行梳理，以确定全球材料集的差距和需求。通过与世界卫生组织现有的合 作，专家们参与了培训大纲的定义以及培训模块内容的填充。由世界卫生组织协调的同行评审和试点测试确保了收集反馈和 输入，以最终完善产品。世界卫生组织 ...

全球呼吸道病毒活动每周更新 第516号 总结至第8周的数据，截止至2025年2月23日。 流感 摘要 • 在北半球，北美（主要为A(H1N1)pdm09）、中美洲和加勒比地区（主要为两种流感A亚型）、热带南美洲（主要为A(H1N1)pdm09和B）、北非（主要为两种流感A亚型 ）、西非（主要为A(H1N1)pdm09）和东非（主要为A(H3N2)和B）、整个欧洲（北欧：两种流感A亚型，其他地区：所有季节性亚型）；西欧（主要为A(H3N2)）、南欧（ 所有季节性亚型）、东南亚（主要为A(H1N1)pdm09和B）以及东亚（主要为A(H1N1)pdm09）。中美洲和加勒比地区、北非、西非和东非的一些国家活动增加，而在热带 南美洲、欧洲和亚洲，活动趋势呈现混合状态。• 在南半球，东非（主要为A(H3N2)和B）和东南亚（主要为A(H1N1)pdm09和B）的单个国家观察到活动升高，以及大洋洲 的多个国家（主要为A(H1N1)pdm09）。总体而言，活动保持稳定或有所下降。 SARS-CoV-2 全球范围内，报告国家中SARS-CoV-2活动持续保持低水平，尽管在中美洲和加勒比地区的一些部分、热带和温带南美洲以及大洋 ...

推荐的2025-2026年度北半球流感季节使用的流感病毒疫苗成分 二〇二五年二月 世界卫生组织召开技术磋商会议 1 每年二月和九月分别推荐应纳入流感疫苗的病毒 2 对于北半 球（NH）和南半球（SH）的流感季节，分别。此建议适用于NH 2025-2026流感季节使用的流 感疫苗。2025年9月将提出关于用于SH 2026流感季节的疫苗的建议。世界卫生组织关于选择热 带和亚热带地区国家使用NH和SH制剂的指南可在世界卫生组织全球流感计划网站上找到。 3 . 1 推荐流感疫苗组成： https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations 2 描述流感疫苗病毒选择和开发的过程： http://www.who.int/gb/pip/pdf_files/Fluvaccvirusselection.pdf 3 疫苗在热带和亚热带地区： https://www.who.int/teams/global-influenza-programme/vaccines/vaccine-in-tropics-and-subtro ...

世界抗生素耐药性意 识周2024活动 2.1 主题 4 2.2 四方协调与合作 4 2.3 资源 4 总结：成功、挑战和经验教训 参与者参与度 6 目录 | 缩写 | 3 | | --- | --- | | 引言 | 4 | 活动策划 4 3.1 世界卫生组织区域办事处 6 3.2 全球抗生素耐药性领导集团 6 3.3 其他内部和外部利益相关者 6 3.4 为AMR活动蓝色行动 7 3.5 媒体互动 7 3.6 青年参与度 8 4.7 AMR感染幸存者的参与度 8 3.8 公民社会的参与 8 3.9 医疗工作者 8 全球事件和活动 9 对社交媒体和媒体报道的分析 9 世界卫生组织区域和国家级办公室的活动 12 世界抗菌素抗性意识周（WAAW）是一项全球性宣传活动，旨在提高公众对抗菌素抗性（AMR）的认识和理 解，并推动医疗工作者、环境保护者、动物卫生专业人员、农学家、农民、政策制定者、青年、民间社会、 媒体和公众采取行动，以应对耐药病原体的出现和传播。WAAW是其中之一 世界卫生组织的官方健康运动 由 世界卫生大会规定。世界卫生组织全球卫生工作者庆祝活动（WAAW）计划在总部、世界卫生组织六个区域 办事处以及 ...

第29期 | 2025年1月 世界卫生组织关于卫生紧急事 件的运营更新 本期 关键数据：世界卫生组织在紧急情况下的工作：2024年回顾 1 世界卫生组织2025年卫生紧急情况呼吁 3 2024年区域性紧急计划：世界卫生组织美洲地区、世界卫生组织欧 洲地区；以及世界卫生组织西太平洋地区 4 准备和就绪 11 世界卫生组织全球卫生紧急事件物流中心 15 健康紧急情况下的学习和能力发展 16 关键链接和有用资源 17 在叙利亚阿拉伯共和国，世界卫生组织（WHO）的一支团队访问了农村阿勒颇马卡纳赫村的一个卫生中心，与健康和社区工作者以及受益者进行了会面（2024年9月）。照片来源：WHO/Farah Ramadan 截至2025年1月15日，世界卫生组织目前正在全球范围内应对42个分级紧急事件，包括： 2024年1月20日，坦桑尼亚 确认了马尔博病毒病的爆发 在西北卡盖拉地区，在调查和实验室分析疑似 病例后，发现一例病毒检测呈阳性。随后，世界卫生组织将该疫情定为2级紧急事件。 持续于下一页…… 关键数据：世界卫生组织在紧急情况下的工作：2024年回顾 应对紧急情况 从1月1日至12月31日，世界卫生组织在六个世界卫生 ...